Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia
HUANG Bin,LIU Xiang,CHENG Yu-qi,BAI Yan,WU Jun-yao,WANG Jia,XIANG Bo,ZHAO Lian-sheng,XU Xiu-feng,LI Tao,MA Xiao-hong
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2013.12.104
2013-01-01
Abstract:Objective To explore the efficacy and safety of aripiprazole orally disintegrating tablets in the treatment of acute schizophrenia.Methods We recruited 167 patients with schizophrenia,they were randomly divided into ariprazole common tablets treatment group and orally disintegrating tablets treatment group.Treatment efficacy were assessment using the Positive and Negative Syndrome Scale(PANSS) reduction rate and the Treatment Emergent Symptom before treatment and after 2 weeks and 4 weeks treatment.Blood routine,liver and kidney function,blood glucose,blood lipid and ECG were tested,before treatment and after 4 weeks treatment.Results After 2 weeks and 4 weeks treatment,effective rate were 2.38% and 61.91% total in commen tablets group.4.82% and 63.86% in orally disintegrating tablets group,the difference between the two groups were not statistically significant.Adverse reactions mostly appeared within 2 weeks after the treatment in two dosage forms,and mainly of them were dizziness,insomnia,lethargy,akathisia and sinus tachycardia.Conclusion Aripiprazole orally disintegrating tablets and commen tablets have positive effect to improve psychiatric symptoms,and show a good safety and tolerability.